Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates

Core Insights - Minerva Neurosciences, Inc. reported business updates and financial results for Q3 2025, highlighting significant financing and clinical trial advancements [1][3]. Business Updates - The company secured $80 million in gross proceeds from a private placement on October 23, 2025, with potential additional proceeds of up to $120 million contingent on warrant exercises related to its Phase 3 trial for roluperidone in schizophrenia [2]. - The CEO emphasized the alignment with the FDA on the Phase 3 clinical trial and expressed confidence in funding the study and preparing for a potential commercial launch of roluperidone in the US [3]. Financial Results - Research and Development (R&D) expenses for Q3 2025 were $0.9 million, down from $1.9 million in Q3 2024, primarily due to reduced costs in drug substance validation and consultant fees [4]. - General and Administrative (G&A) expenses for Q3 2025 were $1.9 million, a decrease from $2.5 million in Q3 2024, attributed to lower professional service fees [5]. - The company reported a net loss of $2.7 million for Q3 2025, compared to a net income of $22.5 million in Q3 2024, reflecting a significant change in financial performance [8]. - Cash and cash equivalents as of September 30, 2025, were approximately $12.4 million, down from $21.5 million at the end of 2024 [9]. Balance Sheet Highlights - Total assets decreased to $28.1 million as of September 30, 2025, from $37.1 million in 2024 [14]. - Total liabilities were reported at $62.7 million, slightly down from $62.8 million in the previous year [14].